AstraZeneca has been refused eventual accelerated assessment in the EU of its PD-L1 blocker, Imfinzi (durvalumab), for stage III lung cancer. This a disappointment for the company, which is keen to get Imfinzi approved as soon as it can for use in patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy – a population where it leads its competitors.
AstraZeneca PLC to date seems not to have filed for approval in the EU for Imfinzi in any indication....






